Reviewing Edesa Biotech Inc. (EDSA)’s and Matinas BioPharma Holdings Inc. (NYSEAMERICAN:MTNB)’s results

As Biotechnology companies, Edesa Biotech Inc. (NASDAQ:EDSA) and Matinas BioPharma Holdings Inc. (NYSEAMERICAN:MTNB) are our subject to compare. And more specifically their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Edesa Biotech Inc. 6 83749.89 N/A -1.16 0.00
Matinas BioPharma Holdings Inc. 1 1210.11 N/A -0.15 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 has Edesa Biotech Inc. and Matinas BioPharma Holdings Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Edesa Biotech Inc. 0.00% -51.1% -48.4%
Matinas BioPharma Holdings Inc. 0.00% -157.2% -59.6%

Volatility & Risk

Edesa Biotech Inc.’s volatility measures that it’s 127.00% more volatile than S&P 500 due to its 2.27 beta. From a competition point of view, Matinas BioPharma Holdings Inc. has a 1.73 beta which is 73.00% more volatile compared to S&P 500.


9.2 and 9 are the respective Current Ratio and a Quick Ratio of Edesa Biotech Inc. Its rival Matinas BioPharma Holdings Inc.’s Current and Quick Ratios are 12.8 and 12.8 respectively. Matinas BioPharma Holdings Inc. has a better chance of clearing its pay short and long-term debts than Edesa Biotech Inc.

Insider & Institutional Ownership

Roughly 25.9% of Edesa Biotech Inc. shares are held by institutional investors while 25.8% of Matinas BioPharma Holdings Inc. are owned by institutional investors. 1.3% are Edesa Biotech Inc.’s share held by insiders. Competitively, Matinas BioPharma Holdings Inc. has 1.9% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Edesa Biotech Inc. -1.21% -31.65% -21.79% -37.91% -44.29% -10.62%
Matinas BioPharma Holdings Inc. 3.84% -5.27% -18.89% -17.23% 114.58% 36.32%

For the past year Edesa Biotech Inc. has -10.62% weaker performance while Matinas BioPharma Holdings Inc. has 36.32% stronger performance.


Edesa Biotech Inc. beats Matinas BioPharma Holdings Inc. on 4 of the 7 factors.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid-based drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an orally-administered cochleate formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of aminoglycoside antibiotic agent amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring strategic partnership options for MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.